Welcome to LookChem.com Sign In|Join Free
  • or
4-Oxo-N-(4-sulfamoylphenyl)-4H-1-benzopyran-2-carboxamide is a complex organic compound with the molecular formula C16H12N2O5S. It is a derivative of benzopyran, a heterocyclic compound with a benzene ring fused to a pyran ring. The molecule features a sulfamoyl group (-SO2NH2) attached to the para position of the phenyl ring, which is connected to the benzopyran core through a carboxamide linkage. 4-Oxo-N-(4-sulfamoylphenyl)-4H-1-benzopyran-2-carboxamide is known for its potential pharmaceutical applications, particularly as an inhibitor of cyclooxygenase enzymes, which are involved in the production of prostaglandins and can be targeted for the treatment of inflammation and pain. The specific structure and properties of 4-Oxo-N-(4-sulfamoylphenyl)-4H-1-benzopyran-2-carboxamide make it a subject of interest in medicinal chemistry and drug development.

3845-20-3

Post Buying Request

3845-20-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3845-20-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 3845-20-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,8,4 and 5 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 3845-20:
(6*3)+(5*8)+(4*4)+(3*5)+(2*2)+(1*0)=93
93 % 10 = 3
So 3845-20-3 is a valid CAS Registry Number.
InChI:InChI=1/C16H12N2O5S/c17-24(21,22)11-7-5-10(6-8-11)18-16(20)15-9-13(19)12-3-1-2-4-14(12)23-15/h1-9H,(H,18,20)(H2,17,21,22)

3845-20-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-oxo-N-(4-sulfamoylphenyl)chromene-2-carboxamide

1.2 Other means of identification

Product number -
Other names 4H-1-BENZOPYRAN-2-CARBOXANILIDE,4-OXO-4'-SULFAMOYL

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3845-20-3 SDS

3845-20-3Downstream Products

3845-20-3Relevant academic research and scientific papers

Chromene-containing aromatic sulfonamides with carbonic anhydrase inhibitory properties

Angeli, Andrea,Kartsev, Victor,Petrou, Anthi,Pinteala, Mariana,Brovarets, Volodymyr,Slyvchuk, Sergii,Pilyo, Stepan,Geronikaki, Athina,Supuran, Claudiu T.

, (2021/05/19)

Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the essential reaction of CO2 hydration in all living organisms, being actively involved in the regulation of a plethora of patho/physiological conditions. A series of chromene-based sulfonamides were synthesized and tested as possible CA inhibitors. Their inhibitory activity was assessed against the cytosolic human isoforms hCA I, hCA II and the transmembrane hCA IX and XII. Several of the investigated derivatives showed interesting inhibition activity towards the tumor associate isoforms hCA IX and hCA XII. Furthermore, computational procedures were used to investigate the binding mode of this class of compounds, within the active site of hCA IX.

Carbonic anhydrase inhibition with sulfonamides incorporating pyrazole-and pyridazinecarboxamide moieties provides examples of isoform-selective inhibitors

Angeli, Andrea,Brovarets, Volodymyr,Geronikaki, Athina,Kartsev, Victor,Panchishin, Svitlana,Petrou, Anthi,Pinteala, Mariana,Supuran, Claudiu T.,Vydzhak, Roman

, (2021/11/30)

A series of benzenesulfonamides incorporating pyrazole-and pyridazinecarboxamides decorated with several bulky moieties has been obtained by original procedures. The new derivatives were investigated for the inhibition of four physiologically crucial human carbonic anhydrase (hCA, EC 4.2.2.1.1) isoforms, hCA I and II (cytosolic enzymes) as well as hCA IX and XII (transmembrane, tumor-associated isoforms). Examples of isoform-selective inhibitors were obtained for all four enzymes investigated here, and a computational approach was employed for explaining the ob-served selectivity, which may be useful in drug design approaches for obtaining inhibitors with pharmacological applications useful as antiglaucoma, diuretic, antitumor or anti-cerebral ischemia drugs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 3845-20-3